FierceBiotechCAR T-Cell therapy sends multiple myeloma into lasting remission …Science DailyIn an early clinical trial, 33 out of 35 (94 percent) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy — chimer… Continue reading
|
ACEA Bio, Memorial Sloan Kettering Collaborate on CAR T Cell Assay
360Dx (subscription) They also will evaluate ACEA’s xCelligence Real-Time Cell Analysis platform to monitor destruction of cancer cells by patients’ own genetically modified CAR T cells. ACEA’s instrument can monitor this cancer-killing process in real-time without the use … |
WPSU |
CRISPR, Five Ways
WPSU CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is the basis for a revolutionary genome-editing technology that allows researchers to make very precise modifications to DNA. The implications are enormous — not only … |
|
CRISPR genome editing may cause unintended mutations
BioNews Until now, ‘off-target effects’ of the CRISPR/Cas9 system were thought to be minimal, with improvements to the technique reducing errors to nearly undetectable levels. However, now a new study suggests previous methods for detecting off-target … |
|
CRISPR may introduce hundreds of unwanted mutations into the genome, a small study finds.
BioNews Until now, ‘off-target effects’ of the CRISPR/Cas9 system were thought to be minimal, with improvements to the technique reducing errors to nearly undetectable levels. However, now a new study suggests previous methods for detecting off-target … |
|
CRISPR, Five Ways
WBAA CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is the basis for a revolutionary genome-editing technology that allows researchers to make very precise modifications to DNA. The implications are enormous — not only … |
FierceBiotech |
CAR T-Cell therapy sends multiple myeloma into lasting remission
EurekAlert (press release) “While it’s still early, these data are a strong sign that CAR T-cell therapy can send multiple myeloma into remission,” said ASCO Expert Michael S. Sabel, MD, FACS. “It’s rare to see such high response rates, especially for a hard-to-treat cancer … ASCO dark horse Nanjing Legend Biotech shines with promising CAR–T dataFierceBiotech Chinese cell therapy effective in small multiple myeloma trialReuters bluebird bio and Celgene Corporation Announce Updated Clinical Results from Ongoing First-in-Human Multicenter …Business Wire (press release) TheStreet.com –Endpoints News all 8 news articles » |